BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tavneos (Avacopan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tavneos (Avacopan)\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06611696-955@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tavneos (Avacopan): Phase 4 readout est. (NCT06611696)
DESCRIPTION:Tavneos (Avacopan)\, phase 4.\nStudy: Avacopan vs Reduced-dose 
 Glucocorticoids in ANCA-associated Vasculitis\nEstimated primary completio
 n: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ava
 copan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06611696
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06321601-955@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20270718
DTEND;VALUE=DATE:20270719
SUMMARY:Tavneos (Avacopan): Phase 3 readout est. (NCT06321601)
DESCRIPTION:Tavneos (Avacopan)\, phase 3.\nStudy: Study to Evaluate Avacopa
 n in Combination With a Rituximab or Cyclophosphamide-containing Regimen\,
  in Children From 6 Years to < 18 Years of Age With AAV.\nEstimated primar
 y completion: 18 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/avacopan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06321601
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06676579-955@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tavneos (Avacopan): Phase 2 readout est. (NCT06676579)
DESCRIPTION:Tavneos (Avacopan)\, phase 2\, Chronic Kidney Disease.\nStudy: 
 Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)\nEstimated prim
 ary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/avacopan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06676579
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07556484-955@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Tavneos (Avacopan): Phase 1 readout est. (NCT07556484)
DESCRIPTION:Tavneos (Avacopan)\, phase 1.\nStudy: Pharmacokinetics Of Emuls
 ified Avacopan Applied By NG Tube\nEstimated primary completion: 1 August 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/avacopan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07556484
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07373262-955@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20300301
DTEND;VALUE=DATE:20300302
SUMMARY:Tavneos (Avacopan): Phase 3 readout est. (NCT07373262)
DESCRIPTION:Tavneos (Avacopan)\, phase 3.\nStudy: Avacopan Added to Standar
 d-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involve
 ment\nEstimated primary completion: 1 March 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/avacopan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07373262
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07176546-955@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Tavneos (Avacopan): Phase 2/3 readout est. (NCT07176546)
DESCRIPTION:Tavneos (Avacopan)\, phase 2/3.\nStudy: TAVNEOS for Otolaryngol
 ogic Manifestations of Granulomatosis With Polyangiitis\nEstimated primary
  completion: July 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/avacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07176546
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06072482-955@assetmemo.bio
DTSTAMP:20261121T005608Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Tavneos (Avacopan): Phase 4 readout est. (NCT06072482)
DESCRIPTION:Tavneos (Avacopan)\, phase 4.\nStudy: A Study to Evaluate Avaco
 pan in Participants With ANCA-associated Vasculitis\nEstimated primary com
 pletion: 31 December 2036. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/avacopan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06072482
URL:https://assetmemo.bio/drug/avacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
